SCHEMBL3369326

SCHEMBL3369326

Cc1ccccc1-c1nc(-c2ccccc2)nc(N)c1C#N

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 11/20 0.71
ADORA1 P30542 10/20 0.71
HSD17B10 Q99714 4/20 0.71
DPP4 P27487 1/20 0.61
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 2/20 0.52
HPGD P15428 2/20 0.52
LMNA P02545 2/20 0.51
ADRA2A P08913 1/20 0.49
HTT P42858 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
NPSR1 Q6W5P4 1/20 0.47
SQOR Q9Y6N5 1/20 0.45
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 1/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3369656 0.82 ADORA1 (0.83) ADORA2AADORA1HSD17B10DPP4ALDH1A1
SCHEMBL3369377 0.80 ADORA2A (0.74) ADORA2AADORA1HSD17B10DPP4KDM4E
SCHEMBL3370611 0.76 ADORA1 (0.70) ADORA2AADORA1HSD17B10DPP4KDM4E
SCHEMBL3372730 0.76 DPP4 (0.65) ADORA2AADORA1HSD17B10DPP4NPSR1
SCHEMBL6871445 0.76 DPP4 (0.67) ADORA2AADORA1HSD17B10DPP4KDM4E
SCHEMBL3369028 0.76 DPP4 (1.00) DPP4
SCHEMBL3369169 0.74 ADORA1 (0.71) ADORA2AADORA1HSD17B10DPP4KDM4E
SCHEMBL28823041 0.73 USP8 (0.57) ADORA2AADORA1HSD17B10DPP4KDM4E
SCHEMBL28822952 0.73 USP8 (0.57) ADORA2AADORA1HSD17B10DPP4KDM4E
SCHEMBL3370624 0.73 ADORA1 (0.76) ADORA2AADORA1HSD17B10DPP4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
CN-1324015-C Pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2007-07-04 CN disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
CN-1630644-A Novel pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2005-06-22 CN disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 ADORA2A 794/4885ADORA1 134/4885HSD17B10 1818/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK ADORA2A 547/4885ADORA1 207/4885HSD17B10 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.